Cargando…

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study

BACKGROUND: Though a single nonmedical switch from the originator infliximab (IFX) to a biosimilar is considered effective and safe for most patients with inflammatory bowel disease (IBD), very limited data are available on multiple successive switches. METHODS: We performed a prospective multicente...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanzel, Jurij, Jansen, Jeroen M, ter Steege, Rinze W F, Gecse, Krisztina B, D’Haens, Geert R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Leading Off
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972297/ https://www.ncbi.nlm.nih.gov/pubmed/34013959 http://dx.doi.org/10.1093/ibd/izab099

Ejemplares similares

Natural History and Risk Stratification of Recurrent Crohn’s Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study
por: Joustra, Vincent, et al.
Publicado: (2021)

Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation
por: Scott, Frank I, et al.
Publicado: (2022)

The Emerging Role of Noncoding RNAs in Pediatric Inflammatory Bowel Disease
por: Jabandziev, Petr, et al.
Publicado: (2020)

The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation
por: Park, K T, et al.
Publicado: (2020)

Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity
por: Fang, Xin, et al.
Publicado: (2020)

Interrogating the Gut-Brain Axis in the Context of Inflammatory Bowel Disease: A Translational Approach
por: Collins, Stephen M
Publicado: (2020)

Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease
por: de Krijger, Manon, et al.
Publicado: (2022)

Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
por: Verstockt, Sare, et al.
Publicado: (2021)

Increased Colonic Epithelial Permeability and Mucosal Eosinophilia in Ulcerative Colitis in Remission Compared With Irritable Bowel Syndrome and Health
por: Katinios, Georgios, et al.
Publicado: (2020)

Lower Impact of Disease on Daily Life and Less Fatigue in Patients With Inflammatory Bowel Disease Following a Lifestyle Intervention
por: Lamers, Carlijn R, et al.
Publicado: (2022)

The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study
por: Holmgren, Johanna, et al.
Publicado: (2022)

Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study
por: Chen, Grace, et al.
Publicado: (2020)

Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD
por: Burgueño, Juan F, et al.
Publicado: (2020)

Multidimensional Impact of Mediterranean Diet on IBD Patients
por: Chicco, Fabio, et al.
Publicado: (2020)

Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn’s Disease
por: Olaisen, Maya, et al.
Publicado: (2020)

Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis—An Exploratory Study to Define Deep Remission
por: Iacucci, Marietta, et al.
Publicado: (2021)

Development of a Personalized Intestinal Fibrosis Model Using Human Intestinal Organoids Derived From Induced Pluripotent Stem Cells
por: Estrada, Hannah Q, et al.
Publicado: (2021)

Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy
por: Abreu, Maria T, et al.
Publicado: (2022)

Molecular and Functional Characterization of Human Intestinal Organoids and Monolayers for Modeling Epithelial Barrier
por: Jelinsky, Scott A, et al.
Publicado: (2022)

Label-Free Characterization and Quantification of Mucosal Inflammation in Common Murine Colitis Models With Multiphoton Imaging
por: Kreiss, Lucas, et al.
Publicado: (2022)

Prediction of Crohn’s Disease Stricturing Phenotype Using a NOD2-derived Genomic Biomarker
por: Ashton, James J, et al.
Publicado: (2022)

Sustained Diet-Induced Remission in Pediatric Crohn’s Disease Is Associated With Kynurenine and Serotonin Pathways
por: Ghiboub, Mohammed, et al.
Publicado: (2023)

Health Care Disparities, Social Determinants of Health, and Emotional Impacts in Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey
por: Odufalu, Florence-Damilola, et al.
Publicado: (2023)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report
por: Strik, Anne S., et al.
Publicado: (2019)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care Setting
por: Volkers, Adriaan, et al.
Publicado: (2023)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

Gait Speed and Confidence Levels in Persons Using 1 and 2 Canes While Walking a 4-m Course
por: Lisenby, Marion A.
Publicado: (2017)

Collaborative research in surgery: a rising tide lifts all boats
por: Li, Elizabeth, et al.
Publicado: (2022)

Collaborative research: population-based data and validation are necessary
por: Björck, Martin
Publicado: (2022)

Shared decision-making should be a standard part of surgical care
por: Ubbink, Dirk T
Publicado: (2022)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Biosimilar Uptake: The Importance of Healthcare Provider Education
por: Oskouei, Sonia Tadjalli, et al.
Publicado: (2021)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Intestinal Ultrasound to Evaluate Treatment Response During Pregnancy in Patients With Inflammatory Bowel Disease
por: De Voogd, Floris, et al.
Publicado: (2021)

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
por: Kim, HoUng, et al.
Publicado: (2020)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_po0gi60g5dijehcka1j3v4lmcu